MX347772B - Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak. - Google Patents

Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak.

Info

Publication number
MX347772B
MX347772B MX2014010613A MX2014010613A MX347772B MX 347772 B MX347772 B MX 347772B MX 2014010613 A MX2014010613 A MX 2014010613A MX 2014010613 A MX2014010613 A MX 2014010613A MX 347772 B MX347772 B MX 347772B
Authority
MX
Mexico
Prior art keywords
fused bicyclic
fak inhibitor
diaminopyrimidine derivative
alk
dual alk
Prior art date
Application number
MX2014010613A
Other languages
English (en)
Other versions
MX2014010613A (es
Inventor
Laurent Courvoisier
R Ott Gregory
J Jacobs Martin
P Allwein Shawn
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47892060&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347772(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of MX2014010613A publication Critical patent/MX2014010613A/es
Publication of MX347772B publication Critical patent/MX347772B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención provee un compuesto de la fórmula (I) (ver Fórmula) o una de sus formas de sal. El compuesto de la fórmula (I) tiene actividad inhibitoria de ALK y FAK, y puede usarse para el tratamiento de trastornos proliferativos.
MX2014010613A 2012-03-06 2013-03-06 Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak. MX347772B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261607305P 2012-03-06 2012-03-06
PCT/US2013/029304 WO2013134353A1 (en) 2012-03-06 2013-03-06 Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor

Publications (2)

Publication Number Publication Date
MX2014010613A MX2014010613A (es) 2014-09-18
MX347772B true MX347772B (es) 2017-05-12

Family

ID=47892060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010613A MX347772B (es) 2012-03-06 2013-03-06 Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak.

Country Status (29)

Country Link
US (5) US9132128B2 (es)
EP (2) EP2822939B1 (es)
JP (2) JP6016953B2 (es)
KR (1) KR102068374B1 (es)
CN (2) CN106166155B (es)
AU (1) AU2013229995B2 (es)
CA (1) CA2865420C (es)
CL (1) CL2014002353A1 (es)
CY (1) CY1117565T1 (es)
DK (1) DK2822939T3 (es)
EA (2) EA025859B1 (es)
ES (2) ES2681487T3 (es)
HK (2) HK1205119A1 (es)
HR (1) HRP20160387T1 (es)
HU (1) HUE027976T2 (es)
IL (2) IL234239A (es)
ME (1) ME02460B (es)
MX (1) MX347772B (es)
MY (1) MY177290A (es)
NZ (1) NZ630251A (es)
PH (1) PH12014501979A1 (es)
PL (1) PL2822939T3 (es)
RS (1) RS54689B1 (es)
SG (2) SG10201507865QA (es)
SI (1) SI2822939T1 (es)
SM (1) SMT201600134B (es)
UA (1) UA115052C2 (es)
WO (1) WO2013134353A1 (es)
ZA (1) ZA201406147B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201507865QA (en) * 2012-03-06 2015-10-29 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016105529A1 (en) 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
CN112996534A (zh) 2018-08-07 2021-06-18 因斯瑞拜奥有限公司 结合间变性淋巴瘤激酶抑制剂进行egf/egfr通路抑制的方法和组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2532800C (en) 2003-07-23 2013-06-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
PL1660458T3 (pl) 2003-08-15 2012-07-31 Novartis Ag 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
EP1713806B1 (en) * 2004-02-14 2013-05-08 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005097765A1 (en) 2004-03-31 2005-10-20 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
CA2642229C (en) * 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
TWI432427B (zh) 2006-10-23 2014-04-01 Cephalon Inc 作為ＡＬＫ及ｃ-ＭＥＴ抑制劑之２，４-二胺基嘧啶之融合雙環衍生物
EP3012249A1 (en) * 2006-12-08 2016-04-27 Novartis AG Compounds and composition as protein kinase inhibitors
MX2009011090A (es) * 2007-04-18 2009-11-02 Pfizer Prod Inc Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal.
CA2764653C (en) * 2009-06-10 2018-01-02 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds
SG10201507865QA (en) * 2012-03-06 2015-10-29 Cephalon Inc Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
KR101446742B1 (ko) * 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2016105529A1 (en) * 2014-12-23 2016-06-30 Cephalon, Inc. Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives

Also Published As

Publication number Publication date
UA115052C2 (uk) 2017-09-11
SI2822939T1 (sl) 2016-04-29
CY1117565T1 (el) 2017-04-26
IL234239A (en) 2017-06-29
US20150374693A1 (en) 2015-12-31
RS54689B1 (en) 2016-08-31
IL252364B (en) 2018-03-29
PL2822939T3 (pl) 2016-08-31
SG10201507865QA (en) 2015-10-29
CN106166155B (zh) 2019-01-18
US9132128B2 (en) 2015-09-15
ME02460B (me) 2017-02-20
ES2681487T3 (es) 2018-09-13
EP2822939B1 (en) 2016-02-17
WO2013134353A8 (en) 2014-06-19
JP2015509540A (ja) 2015-03-30
US9623026B2 (en) 2017-04-18
JP2017039741A (ja) 2017-02-23
AU2013229995A1 (en) 2014-09-25
EP2822939A1 (en) 2015-01-14
IL252364A0 (en) 2017-07-31
AU2013229995B2 (en) 2017-04-13
EA025859B1 (ru) 2017-02-28
HUE027976T2 (en) 2016-11-28
US10111872B2 (en) 2018-10-30
PH12014501979B1 (en) 2014-11-24
EP3056494B1 (en) 2018-05-02
WO2013134353A1 (en) 2013-09-12
US20170173017A1 (en) 2017-06-22
SG11201405371PA (en) 2014-09-26
US9339502B2 (en) 2016-05-17
US10632119B2 (en) 2020-04-28
US20160243119A1 (en) 2016-08-25
CN104159894A (zh) 2014-11-19
MY177290A (en) 2020-09-10
EP3056494A1 (en) 2016-08-17
KR102068374B1 (ko) 2020-01-20
CN106166155A (zh) 2016-11-30
MX2014010613A (es) 2014-09-18
ZA201406147B (en) 2015-12-23
NZ630251A (en) 2016-02-26
DK2822939T3 (en) 2016-03-14
JP6016953B2 (ja) 2016-10-26
ES2570976T3 (es) 2016-05-23
SMT201600134B (it) 2016-07-01
HK1205119A1 (zh) 2015-12-11
US20150011561A1 (en) 2015-01-08
HK1226300A1 (zh) 2017-09-29
CA2865420A1 (en) 2013-09-12
EA201491641A1 (ru) 2015-04-30
CN104159894B (zh) 2016-09-07
KR20140138247A (ko) 2014-12-03
EA033124B1 (ru) 2019-08-30
US20190328735A1 (en) 2019-10-31
PH12014501979A1 (en) 2014-11-24
EA201691574A1 (ru) 2017-03-31
CA2865420C (en) 2020-06-02
CL2014002353A1 (es) 2015-01-09
HRP20160387T1 (hr) 2016-05-20

Similar Documents

Publication Publication Date Title
MX2018000396A (es) Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4).
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
AU2015207757A8 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of SHP2
PH12015500689B1 (en) Azaquinazoline inhibitors of atypical protein kinase c
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
MX366308B (es) Derivados de amida como bloqueadores de ttx-s.
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
AU2015292632B2 (en) Aldosterone synthase inhibitors
PH12014501979A1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
IN2014DN08443A (es)
MX2017005669A (es) Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos.
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти

Legal Events

Date Code Title Description
FG Grant or registration